Maia Kipman


Maia Kipman
BS, Cognitive Neuroscience & Performance Studies
Brown University
Providence, RI
MD, PhD Student in Neuroscience
David Walt, PhD, Adviser




Parkinson’s Disease (PD) is the second most common neurodegenerative disorder following Alzheimer’s Disease. To date, research aimed at identifying a biomarker for PD has, for the most part, focused on measuring the levels of all isoforms of a given protein such as alpha-synuclein or DJ-1 in serum or CSF. These methods, however, have not had the sensitivity and specificity necessary to be used as an indicator of disease. Recent evidence suggests that specific post-translational modifications such as phosphorylation and ubiquitination are key to the pathophysiology of PD. These post-translationally modified proteins have not yet been measured in serum because the concentrations of these isoforms are likely below the limit of detection of conventional ELISAs. I hypothesize that the detection of post-translationally modified proteins will be critical to PD biomarker development. Therefore, I will use technology, newly developed in our lab, which is 100-1000 times more sensitive than traditional ELISA to detect these isoforms. During my PhD I will create a panel of SiMoAs assays specific for post-translationally modified proteins relevant to PD.

Apply to the Sackler School


The priority application deadlines are as follows:

December 1: Basic Science Division PhD Programs

February 15: Building Diversity in Biomedical Sciences

March 31: Post-Baccalaureate Research Program

May 1: Clinical & Translational Science, MS in Pharmacology & Drug Development

June 15: Online Certificate in Fundamentals of Clinical Care Research